Genetics

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

Retrieved on: 
Thursday, February 17, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Sangamo Therapeutics, Patient, Webcast, Investor, ID, Therapy, Nasdaq, Telephone, Company, Technology, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022.
  • ET, which will be open to the public via telephone and webcast.
  • The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers.
  • Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations .

23andMe to Present at Citi’s 2022 Virtual Healthcare Conference

Retrieved on: 
Thursday, February 17, 2022
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Time, 23andMe, SEC, Degenerative disease, U.S. Securities and Exchange Commission, Security (finance), Genome, Securities Act of 1933, CA, Securities Exchange Act of 1934, Therapy, Terminology, FDA, Publication, Citigroup, Growth, Research, Conference, Investor, Interest, GLOBE, Pharmaceutical industry

SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi 2022 Virtual Healthcare Conference on February 24, 2022 at 1:15 pm Eastern Time.

Key Points: 
  • SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi 2022 Virtual Healthcare Conference on February 24, 2022 at 1:15 pm Eastern Time.
  • The latest information on this and other events, including any changes to presentation date and time, can also be found there.
  • 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports.
  • The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits.

Mining for Miracles Eyes 2022 Completion of $3.385 Million Fundraising Goal to Establish Cellular and Regenerative Medicine Centre (CRMC) at BC Children’s Hospital

Retrieved on: 
Thursday, February 17, 2022
Health, BC Children's Hospital Foundation, Arrhythmia, Hospital, Biological therapy for inflammatory bowel disease, Epilepsy, British Columbia Children's Hospital, Uncertainty, Cancer, Head, Risk, Man, Social media, Mining, Cardiac arrest, GLOBE, Miner, Cell, Division, Dream, Woman, Diabetes, Regenerative medicine, Child, Acquisition, Blood, Arrest, Leg, Research, Diagnosis, Genetics, Industry, Property management, Pharmaceutical industry, Health insurance, Dentistry, Teck, BC, Cardiology

VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mining for Miracles, the BC mining industrys long-standing fundraising campaign for BC Childrens Hospital Foundation, launched its 2022 campaign today with Premier John Horgan, in support of BC Childrens Hospitals Cellular and Regenerative Medicine Centre (CRMC), the first of its kind in Western Canada.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mining for Miracles, the BC mining industrys long-standing fundraising campaign for BC Childrens Hospital Foundation, launched its 2022 campaign today with Premier John Horgan, in support of BC Childrens Hospitals Cellular and Regenerative Medicine Centre (CRMC), the first of its kind in Western Canada.
  • In 2022, Mining for Miracles launches the final leg of their campaign to fulfill their commitment, made in 2020, to establish the CRMC, a $3.385 million initiative.
  • We receive incredible support for the annual Mining for Miracles campaign from the thousands of women and men who work in the mining industry.
  • BC Childrens has the clinical and scientific expertise to be leaders in pediatric cellular and regenerative medicine, but they require infrastructure and equipment to do this.

AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, February 16, 2022
Amyotrophic lateral sclerosis, NYU, Patient, Hypertensive emergency, Technology, Prognosis, AI, Degenerative disease, Sarcoidosis, Respiratory tract, Department, Fortress Biotech, Evolutionism, Harvard University, Innovation, Tesseract, Leadership, Environment, Therapy, PIKFYVE, ALS, Butterfly network, Biotechnology, Deep learning, Yale University, Board, Bachelor of Arts, Fortune, Disease, BOS, Physical organic chemistry, Ligand Pharmaceuticals, Third Point Management, PAH, National Medal, DNA, Neuroscience, Intelligence, GLOBE, Coronavirus Scientific Advisory Board (Turkey), Medical device, Pharmaceutical industry, Chemistry, Genetics, Physics

GUILFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the appointment of Brigette Roberts, M.D.

Key Points: 
  • GUILFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the appointment of Brigette Roberts, M.D.
  • AI Therapeutics has a tremendous opportunity to help advance drug treatments for underserved patients suffering from rare diseases.
  • I am honored to lead AI Therapeutics, as we work diligently to improve the prognosis for these patients, one disease at a time.
  • AI Therapeutics is part of biotechnology accelerator 4Catalyzer, which has launched Butterfly Network, Quantum-Si, Hyperfine and Liminal Sciences, Detect, Tesseract, and Protein Evolution.

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

Retrieved on: 
Wednesday, February 16, 2022
NASDAQ, Health, CEO, Risk, Prequel, HIV disease progression rates, Genetic testing, International, Precision medicine, Association for Molecular Pathology v. Myriad Genetics, Inc., Myriad Genetics, MYGN, Myriad, Genetics, SALT, GLOBE, Internet service provider, Pharmaceutical industry

SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m.

Key Points: 
  • SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m.
  • The companys quarterly earnings will be released the same day prior to the market opening.
  • During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriads performance for the period ending December 31, 2021.
  • Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Tuesday, February 15, 2022
Genentech, Income, Rheumatoid arthritis, Conversation, Cancer, EUA, GAAP, COVID, COVID-19, Result, Public expenditure, Analysis, U.S. Securities and Exchange Commission, MRD, Security (finance), Infection, GLOBE, Terminology, Multiple sclerosis, EBITDA, ADPT, Biology, FDA, Risk, Disease, Degenerative disease, Depreciation, Industry, Growth, Research, Income tax, Diagnosis, Genetics, Drug discovery, Financial condition report, Adjustment, TCR, Pharmaceutical industry, Video game, Lithium, Bookkeeping, Insurance, Life insurance, Ulcerative colitis

Revenue was $37.9 million for the quarter ended December 31, 2021, representing a 26% increase from the fourth quarter in the prior year.

Key Points: 
  • Revenue was $37.9 million for the quarter ended December 31, 2021, representing a 26% increase from the fourth quarter in the prior year.
  • Sequencing revenue was $23.1 million for the quarter, representing an 81% increase from the fourth quarter in the prior year.
  • Operating expenses were $99.5 million for the fourth quarter of 2021, compared to $74.4 million in the fourth quarter of the prior year, representing an increase of 34%.
  • Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2021 financial results after market close on Tuesday, February 15, 2022 at 4:30 PM Eastern Time.

JScreen Honors February as National Cancer Prevention Month

Retrieved on: 
Tuesday, February 15, 2022
Breast cancer, Health, Ovary, Breast Cancer Awareness Month, National Cancer Institute, Awareness, Marketing, Ovarian cancer, Risk, Man, Incidence, Education, National Outreach Programme, Genetic testing, Genetic counseling, Heredity, Goal, Breast, Lists of diseases, Association, Insurance, Woman, Prostate, Disease, Genetics, Skin, Emory University, GLOBE, Gene, Vaccine, Birth control, Cancer

ATLANTA, Feb. 15, 2022 (GLOBE NEWSWIRE) -- JScreen , a national non-profit public health initiative dedicated to preventing genetic diseases, announces its participation in National Cancer Prevention Month in February of 2022.

Key Points: 
  • ATLANTA, Feb. 15, 2022 (GLOBE NEWSWIRE) -- JScreen , a national non-profit public health initiative dedicated to preventing genetic diseases, announces its participation in National Cancer Prevention Month in February of 2022.
  • To do this, JScreen offers its CancerGEN test: an easy, at-home saliva test that screens for genetic risks for many types of cancer.
  • With the majority of Cancer Awareness Months occurring in the fall, such as Breast Cancer in October, and Prostate and Ovarian Cancer in September, JScreen emphasizes the importance of maintaining the same level of awareness year-round.
  • CancerGEN, JScreen's cancer genetic test, analyzes more than 60 cancer susceptibility genes associated with hereditary risks for breast, ovarian, prostate, colorectal, skin, and many other cancers.

North American Genome Sequencing Market Growth Forecasts to 2030: A $10.77 Billion Market by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 17, 2022
Health, Genetics, Country, Cancer, Government, Incidence, Genomics, Agriculture, Speciality chemicals, Technology

The "North America Genome Sequencing Market 2020-2030 by Product, Technology, Application, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Genome Sequencing Market 2020-2030 by Product, Technology, Application, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • The North American genome sequencing market is projected to grow by 11.5% annually in the forecast period and reach $10.77 billion by 2030, driven by the growing government funding to encourage genomics projects, the increasing of the incidence of the cancer and the increasing applications of next-generation sequencing, and the utilization of genomics in specialized or personalized medicine.
  • Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
  • Based on Technology, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, February 17, 2022
Research, FDA, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, Memorial Sloan Kettering Cancer Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Leukemia, Patient, LAIR1, Drug development, Food, Cancer, Record, Lymphatic system, LLS, California Institute for Regenerative Medicine, National, CMML, Company, National Cancer Institute, Priority review, Immunotherapy, Review, Immune tolerance, B cell, Acute myeloid leukemia, Tumor microenvironment, IND, Accelerated approval (FDA), Therapy, Chronic myelomonocytic leukemia, NCI, LILRB4, University, LinkedIn, Albert Einstein College of Medicine, Biology, CIRM, Biotechnology, Twitter, ILT3, FDA, Regenerative medicine, NIH, Research, University of Texas at Austin, ILT4, AML, Fast Track, Leukemia & Lymphoma Society, LILRB2, Pharmaceutical industry, Vaccine, Nature

The Company received Orphan Drug Designation for IO-202 for the treatment of AML in 2020.

Key Points: 
  • The Company received Orphan Drug Designation for IO-202 for the treatment of AML in 2020.
  • Drugs that receive Fast Track designation may be eligible for more frequent interactions and written communications with the FDA to discuss the development plan and data collection to support an approval pathway.
  • LILRB4, also known as ILT3, is an immune inhibitory transmembrane protein found on monocytic myeloid cells, including dendritic cells.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Retrieved on: 
Thursday, February 17, 2022
Research, Technology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Data Management, Science, Other Science, Patient, Tissue, Biomarker, Data science, Cardiac muscle, HIV disease progression rates, Safety, Technology, LinkedIn, Compass, Twitter, Glycogen, Therapy, Pharmacokinetics, Research, Glycogen storage disease type II, Drug discovery, Toxicity, Gene, GAA, Pharmaceutical industry, Vaccine, Maze

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the companys Phase 1 clinical trial of MZE001 in healthy volunteers.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the companys Phase 1 clinical trial of MZE001 in healthy volunteers.
  • MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with late-onset Pompe disease.
  • The initiation of this study is a significant milestone for both Maze and the Pompe community as we advance into the clinic with a potentially disease-modifying treatment for patients, said Sarah Noonberg, M.D., Ph.D., chief medical officer of Maze.
  • In preclinical disease models, treatment with MZE001 has demonstrated potent and selective inhibition of GYS1, leading to reduced accumulation of glycogen through a substrate reduction approach.